There is an increased demand for vaccines to prevent and/or treat illness and mortality caused by the infectious diseases. We have recently established that liposomes composed of cationic lipids act as adjuvant for nasal vaccine formulation. However, the molecular mechanism(s) behind the adjuvant effect remain unrevealed. To this end, we have studied the enhancement of antigen uptake by murine dendritic cell line, DC2.4 cells, by the cationic liposomes and the specific pathways involved in the process. We have observed that the uptake of ovalbumin (OVA) into DC2.4 cells is greatly increased when co-cultured with the cationic liposomes composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl] (DC-chol). However, this enhancement was blocked by pretreatment of DC2.4 cells with chlorpromazine and methyl-β-cyclodextrin, indicating the involvement of clathrin-and caveolin-independent lipid raft-dependent endocytic pathways in the process. Our results implied, at least in part, that enhanced uptake of antigens induced by the cationic liposomes could be a possible mechanism for the induction of immune responses. Although further studies are needed to understand the precise mechanisms behind the adjuvant effects of DOTAP/DC-chol liposome, this approach is quite useful for the development of vaccine system to combat various diseases.
While numerous adjuvants have been explored experimentally, their translation to clinical usage in humans is extremely slow. Thus a clinical need for the development of novel adjuvants arises. Adjuvants generally exhibit their immune-enhancing activities to the antigens through the following mechanisms: 1) the depot effect by which releases antigen from adjuvant carriers at the site of injection gradually, 2) activation of host innate immune responses and 3) increased antigen uptake by antigen-presenting cells (APCs) and in turn its presentation to T cells [9] .
Dendritic cells (DCs) are one of the most favored targets for vaccine delivery because of their primary role in the initiation of acquired immune responses via antigen internalization followed by antigen processing and presentation to lymphocytes, especially to T cells via the major histocompatibility complex (MHC) molecules [10] [11] . Nanoparticles such as liposomes and gold nanoparticles are now considered to be not only efficient drug carriers but also potent adjuvants useful for vaccine formulations. For example, a nanogel composed of cholesteryl-group-bearing pullulan acts as an adjuvant by promoting antigen delivery to dendritic cells [12] [13] . Similarly, a well-known carrier for nucleic acid delivery, polyethyleneimine (PEI), is reported to be a potent adjuvant as the release of host double-stranded DNA (dsDNA) into the extracellular milieu triggers Ifr3-dependent innate immune signaling [14] .
Cationic liposome is recognized as a powerful tool for vaccine development as well as for nonviral gene delivery system [15] [16] [17] [18] . We recently demonstrated that the cationic liposomes composed of 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) and 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl] (DC-chol), termed as DOTAP/DC-chol liposomes, are served as a potent adjuvant. The detailed molecular mechanism(s) behind the adjuvant effects of the cationic liposomes are not completely elucidated. We have previously reported that cationic liposome promotes antigen uptake into the DCs located at nasal-associated lymphoid tissues (NALTs) in vivo [19] [20] . Although, how the cationic liposome increases antigen uptake by DCs remains unclear till date. In general, the difference in the uptake mechanism(s) of particulate and soluble forms of antigenic proteins by DCs might be the reason behind this increase in uptake efficiency of antigens 
Bromide thiazolyl blue (MTT) was obtained from NacalaiTesque (Kyoto, Japan).
4',6-diamidino-2-phenylindole (DAPI), chlorpromazine hydrochloride, cytochalasin D, and methyl-cyclodextrin were purchased from Merck (Darmstadt, Germany). Amiloride hydrochloride was purchased from Cayman Chemical Company (Ann Arbor, MI, USA).
Preparation of Cationic Liposomes
Liposomes were prepared as described earlier [19] . Briefly, 10 μmol of total lipids (DOTAP:DC-chol at 1:1 mol ratios) were evaporated to dryness in a glass tube and desiccated for at least 1 h in vacuo. The resultant lipid films were hydrated by the addition of 250 μl of phosphate-buffered saline (PBS; Wako Pure Chemical Industries, Tokyo Japan)) and then vortexed for 5 min at room temperature (RT). The prepared multilamellar vesicles were extruded 10 times by passing through a 100 µm-pore polycarbonate membrane (Advantec, Tokyo, Japan) and then sterilized by filtration through 0.45 μm filter membranes (Iwaki, Tokyo, Japan). The particle size and ζ-potential of the liposomes were measured 
In Vitro Cytotoxic Assay
The cytotoxic effects of the liposomes on DC2. The fixed cells were washed extensively and were mounted in 90% glycerol in PBS containing 1 μg/mL of DAPI for nuclear staining. Confocal images were acquired using an FV1000-D confocal microscope (Olympus, Tokyo, Japan).
Flow Cytometry

Statistical Analysis
Statistical differences in cytotoxicity assay and internalization assay were assessed using one-way ANOVA with Bonferroni's post-hoc test and unpaired t-test with Welch's correction, respectively. 
Results
Toxicity of the Cationic Liposomes on
Effect of the Cationic Liposomes on OVA Uptake by DC2.4 Cells
We evaluated whether the cationic liposome promotes OVA uptake by DC2.4 cells in vitro. The cationic liposomes markedly increased the uptake of OVA by DC2.4 cells compared to an OVA alone-treated group as evidenced by an increase in MFI (39.6 ± 12.8 and 14.3 ± 2.5, respectively) by flow cytometry analysis (Figure 2(a) ). Furthermore, confocal microscopic analysis also supported the increased uptake of OVA when combined with the cationic liposomes ( Figure  2(b) ). These results revealed that cationic liposomes enhance the cellular uptake of OVA in murine dendritic cells, thereby acting as a carrier for antigen delivery.
Mechanism of Enhanced Uptake of OVA by the Cationic Liposomes
It is well-known that most endocytic pathways are energy-dependent and hence are inhibited at low temperatures (e.g. 4˚C) [28] [29] . Therefore, we have examined the temperature-dependency of OVA internalization in DC2.4 cells to understand the possible mechanisms of enhancement in uptake by the cationic liposomes. Figure 3 shows that OVA internalization is increased by the cationic liposomes at 4˚C (MFI 26.7) which is otherwise inhibited (MFI 11.1), suggesting the involvement of energy-dependent endocytic pathways in the process. Various endocytic pathways, including phagocytosis, clathrin-mediated endocytosis (CME), lipid raft-mediated endocytosis, and macropinocytosis, are orchestrated to internalize a variety of molecules into the cell compartments [30] [31]. To identify the precise mechanism(s) of endocytosis mediating the increased uptake of OVA by the cationic liposomes, the effect of perturbation of endocytic pathways by various chemical inhibitors (Table 1) were examined ( Figure 4) . The Open Journal of Immunology increased by the addition of the cationic liposomes may be mediated by clathrinand caveolae-independent lipid raft-mediated endocytic pathways.
Complex Formation Is Crucial for the Uptake of OVA Enhanced by the Cationic Liposomes
OVA is a typical acidic protein (pI = 4.7) it and possesses a negative charge. with cationic liposomes. In the latter case, the cells were treated with cationic liposomes first and OVA was added after washing out these liposomes. Figure 8 shows that increased uptake of OVA by liposomes could not be observed if 
Discussion
We have reported that the cationic liposome composed of DOTAP and DC-chol acts as a potent adjuvant in mice. However, the underlying mechanism(s) were mostly unknown. In this study, we have investigated the pathways by which OVA is taken up by murine DCs cell line, DC2.4 cells, when co-cultured with the cationic liposomes, to evaluate whether specific endocytic pathways are contributing to antigenic delivery to APCs by the cationic liposomes. Our data herein show the following findings: 1) addition of cationic liposomes together Open Journal of Immunology Recently there has been an increase in demand of safe and effective adjuvant which can enhance the immune response to the antigenic protein [36] . Generally, adjuvants exhibit their immune-enhancing activities against antigenic protein through the following mechanisms: 1) the depot effect that gradually releases antigen from adjuvant carriers at the site of administration, 2) activation of host innate immune responses, and 3) increased antigen uptake by APCs and presentation toward T cells. However, research suggested that the depot effect will be 
Conclusions
This study indicated that cellular uptake of antigens may be important for the adjuvant effects of the cationic liposome. Additionally, since the cationic liposomes exert cellular toxicity at higher concentrations both in vitro and in vivo, the use of these liposomes may pose a danger by releasing DAMPs at the site of administration. We are currently testing this possibility to understand the molecular mechanism(s) behind the adjuvant effects of cationic liposomes. This information may lead to development of efficient vaccine systems using liposomal formulations. Open Journal of Immunology
In this study, we have shown that DOTAP/DC-chol liposomes enable dendritic cells to internalize antigenic proteins. This phenomenon might be mediated by clathrin-and caveolin-independent lipid raft-dependent endocytic pathways. Our results revealed, at least in part, that enhancement of antigen uptake by the cationic liposomes could be a possible mechanism behind the induction of antigen-specific immune responses by cationic these liposomes. Although further studies are needed to understand the precise mechanisms of adjuvant effects of DOTAP/DC-chol liposome, this approach is quite useful for the development of vaccine system to combat various diseases. One such study is in progress for the development of nasal pneumonia vaccine using liposomal formulations.
